Grufity logo
Grufity logo
GOSS

GOSS - Gossamer Bio Inc Stock Price, Fair Value and News

$10.76+0.03 (+0.28%)
Market Closed as of 14 Sep 2026, 04:00 pm ET

GOSS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

GOSS Price Action

Last 7 days

-23.1%

Last 30 days

7073.3%

Last 90 days

6229.4%

Trailing 12 Months

211.0%

GOSS RSI Chart

GOSS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

GOSS Valuation

Market Cap

5.3B

Price/Earnings (Trailing)

-42

Price/Sales (Trailing)

98.71

EV/EBITDA

-0.45

Price/Free Cashflow

-32.34

GOSS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

GOSS Fundamentals

GOSS Revenue

Revenue (TTM)

53.3M

Rev. Growth (Yr)

-19.59%

Rev. Growth (Qtr)

-45.51%

GOSS Earnings

Earnings (TTM)

-125.2M

Earnings Growth (Yr)

144.16%

Earnings Growth (Qtr)

136.22%

GOSS Profitability

EBT Margin

-317.64%

Return on Equity

133.17%

Return on Assets

-162.91%

Free Cashflow Yield

-3.09%

GOSS Investor Care

Shares Dilution (1Y)

115.05%

Diluted EPS (TTM)

-0.7

Revenue & Growth

How Gossamer Bio Inc generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
202655.5M53.3M--
2025124.6M40.2M44.1M48.5M
2024---114.7M
2023----
2022----
2021----
20205.0M4.5M4.0M3.4M
2019---5.6M
2018---1.7M
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Gossamer Bio Inc

GOSS
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
 CEO
 WEBSITEgossamerbio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES178

Gossamer Bio Inc Frequently Asked Questions

GOSS is the stock ticker symbol of Gossamer Bio Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Sep 14 2026, market cap of Gossamer Bio Inc is 5.26 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Sep 14 2026, GOSS's PE ratio (Price to Earnings) is -42 and Price to Sales (PS) ratio is 98.71. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GOSS PE ratio will change depending on the future growth rate expectations of investors.